| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health.
NEW YORK, Oct. 27, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a U.S. Department of Veterans Affairs (VA)–backed study evaluating the potential of glial cell line–derived neurotrophic factor (GDNF)as a novel therapy for obesity and fatty liver disease (hepatic steatosis).
The program, led by Dr. Srinivasan and her research team at the Atlanta VA Medical Center, will explore the ability of GDNF to induce weight loss and promote resolution of fatty liver disease through metabolic and neurotrophic mechanisms.
Posted In: HOTH
